Our State-of-the-Art Review on Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses is now out on @JACCCardioOncology @JACCJournals 👇. Role of current multimodality imaging and future directions for their applications:.👥For

🎯To evaluate the relationship between CMR-imaging and pro-fibrotic/inflammatory serum biomarkers, to discriminate HFpEF from associated comorbid conditions. 👥Prospective cohort study of 35 obese participants (mean age 64 ± 8 yrs, 23% females), including:.- 16 with T2DM.- 13

RT @FeliceGragnano: Prevention of #AFib with SGLT2-I across the spectrum of cardiovascular disorders: a meta-analysis of RCTs 📊. 🔗 https://….

RT @iheartfunction: 🚫Therapeutic impasse? Not anymore. Refractory heart failure is becoming a catalyst for change — in strategy, in collabo….

🔥Proud to share that #CardiovascularDiabetology has achieved a new Impact Factor of 10.6 - its highest since 2009 - reinforcing its position among the leading journals in the Cardiovascular and Endocrinology & Metabolism fields. 🎯The journal now ranks 14th out of 230 in the

💊#SGLT2i have emerged as potential cardioprotective agents, reducing cardiovascular mortality and improving #HF outcomes. 🎯Recent evidence suggests that SGLT2i exert anti-inflammatory effects, particularly through modulating the #inflammasome pathway. 🔥This review explores

🎯To evaluate the impact of #SGLT2i on the risk of acute kidney injury (AKI) in #T2DM pts w/ severe #AS undergoing #TAVI. 👥 Multicenter Registry of consecutive pts stratified by the presence of CKD and anti-diabetic therapy (2021-2024). 🔥Our main findings were: .- SGLT2i

RT @iheartfunction: GDMT and LVEF: from static measure to trajectories of change. Journal Club review📷 The clinica….

🚨We're thrilled to launch Cardiovascular Diabetology’s #KnowTheAuthors project - giving visibility to the brilliant minds behind the science!. 🎥 First up: Maria Barranco-Altirriba presents key insights from her study on lipidomics and subclinical carotid atherosclerosis in T2D

Proud of the amazing Teamwork by the entire Cardiology Team at #AziendaOspedalieraSantAndrea for the two Live Cases broadcast globally during #EuroPCR2025. This is a significant recognition of the teamwork, expertise, and innovation we bring to patient care every day!! 🔥🔥🔥

🥳Welcome to our New Associate Editors for #CardiovascularDiabetology - @BioMedCentral . ⭐️Dr. Idit Goldfracht, PhD.Columbia University, New York City, USA. Expertise: Tissue engineering, stem cells, cardiovascular disease, 3D printing, biomaterials, vascularized 3D tissues,

RT @iheartfunction: 🎥Key insights from the #ImprovingHeartFunction session on refractory #heartfailure at #EuroPCR with Jozef Bartunek and….

RT @iheartfunction: 🎤Coming out of the #ImprovingHeartFunction session "Decompensated heart failure: indication and management of mechanica….

👉Pts with both AS and DM face challenges arising from the interaction between the 2 conditions. 🎯To investigate the effects of DM on the LV remodelling in AS patients, specifically focusing on the inflammatory response and oxidative stress. 👥 LV myocardial biopsies were

RT @ehj_ed: Emerging data suggests that one-size-fits-all troponin thresholds may miss the mark, especially in older adults. Read more in #….

RT @iheartfunction: 📢Meet the #iHF Social Media Team: @ARakisheva @belmontemarta1 @MCasenghi @DavidDuncker @EGallinoro @P_Paolisso @EchoSol….

🎯To assess cardiovascular, metabolic, and renal effects of combination therapy w/ GLP-1RA+SGLT2i compared to SGLT2i alone. 👥Komodo’s Healthcare Map (2017- 2023) including 100,455 people in the combination GLP-1RA+SGLT2i group and 339,540 people in the SGLT2i alone group,

RT @MCasenghi: 🔬 New study on TAVI with Navitor THV available at: 🫀 Key procedural predictors of PPI:.✔️ Implantat….